Medically reviewed by Gagandeep Brar, MD Key Takeaways A high platelet count can lead to blood clots and bleeding, which can ...

A recent study identified trends in blood counts, but did not find statistically significant associations between achieving hematological remission and clinical outcomes in polycythemia vera (PV) or ...

The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy. A second phase 3 clinical trial has been ...

Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...

While in nursing school, a patient recognized potential signs of a blood disorder and advocated for further testing, leading to an early diagnosis of essential thrombocythemia. Despite initial ...

Please provide your email address to receive an email when new articles are posted on . Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute, discussed the study, that ...

John Mascarenhas, MD, discusses phase 1 data showing that INCA33989 is a well-tolerated therapy for calreticulin–mutant essential thrombocythemia, with early signs of efficacy and potential disease ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...

Enrollment completed with 73 patients in April 2022 Of the 32 patients treated with bomedemstat for more than 24 weeks: 97% (31/32) achieved platelet count reduction to ≤400 x 109/L. 94% (30/32) ...